University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

N-Methyl-N-formylhydrazine (CAS 758-17-8)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
no test no test gal liv lun vsc gal liv lun vsc no test 1.37m,v

Hamsters: Cancer Test Summary
Hamster Target Sites TD50
(mg/kg/day)
Male Female
gal liv gal liv 5.8m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   gal = gall bladder. liv = liver. lun = lung. vsc = vascular system. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

N-Methyl-N-formylhydrazine: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

N-METHYL-N-FORMYLHYDRAZINE 758-17-8 3788 H f syg wat 24m24 716 0 10.6mg Toth;zkko,93,109-121;1979 --- mhs e 4.71mg P<.0005 + 2.73mg 8.73mg 0/13 24/31 liv mix e 11.3mg P<.0005 + 6.50mg 21.9mg 0/79 19/41 liv lcc e 25.1mg P<.0005 12.2mg 64.5mg 0/79 10/41 liv hpt e 28.3mg P<.0005 13.3mg 77.2mg 0/79 9/41 gal mix e 29.1mg P<.5 + 8.75mg n.s.s. 0/1 3/14 lun tum e no dre P=1. 92.8mg n.s.s. 0/100 0/44 tba mix e 6.04mg P<.0005 3.63mg 11.3mg 13/100 32/44 3789 H m syg wat 24m24 716 0 9.36mg liv mix e 7.55mg P<.0005 + 4.57mg 13.6mg 0/65 24/43 --- mhs e 12.7mg P<.002 + 6.13mg 41.1mg 0/16 10/26 liv hpt e 13.3mg P<.0005 7.35mg 27.4mg 0/65 16/43 bil mix e 19.7mg P<.007 + 8.45mg 218.mg 0/16 7/26 gal mix e 25.3mg P<.002 + 11.4mg 89.1mg 0/34 8/37 liv lcc e 30.0mg P<.0005 13.5mg 88.4mg 0/65 8/43 gal ppa e 42.5mg P<.01 16.1mg 1.95gm 0/34 5/37 lun tum e no dre P=1. 85.4mg n.s.s. 0/88 0/46 tba mix e 4.89mg P<.0005 3.04mg 8.58mg 7/88 34/46 3790 M f swa wat 65w73 1110 0 15.6mg 31.2mg Toth;jnci,60,201-204;1978 lun mix aes 6.44mg \ P<.0005 + 3.77mg 13.3mg 15/100 30/48 (9/37) liv mix aes 10.4mg * P<.0005 + 6.44mg 18.8mg 0/33 22/43 3/11 liv hpt aes 19.5mg * P<.0005 + 10.7mg 47.2mg 0/33 12/43 3/11 liv lcc aes 19.9mg \ P<.0005 + 9.67mg 59.0mg 0/33 10/43 (0/11) gal ade aes 31.5mg * P<.008 + 11.9mg 510.mg 0/29 4/23 1/5 3791 M f swa wat 23m23 1265 0 2.00mg 4.00mg Toth;nplm,27,25-31;1980 lun mix aes .921mg * P<.0005 + .636mg 1.37mg 15/99 39/49 47/50 blv mix aes 6.04mg * P<.0005 + 3.49mg 14.5mg 8/95 10/44 20/48 gal mix aes 57.9mg * P<.02 17.5mg n.s.s. 0/82 0/44 3/48 liv bhp aes 24.7mg * P<.2 4.02mg n.s.s. 0/32 1/10 0/5 3792 M f swa wat 23m24 1266 0 .500mg 1.00mg Toth;myco,78,11-16;1982a lun mix aes .745mg * P<.0005 + .444mg 1.77mg 29/94 31/48 32/48 lun adc aes 1.12mg * P<.0005 .665mg 2.72mg 14/94 23/48 22/48 lun ade aes 1.50mg * P<.002 .779mg 7.82mg 20/94 23/48 21/48 liv hpt aes 9.23mg * P<.2 - 2.27mg n.s.s. 0/50 2/23 0/17 liv agm aes 23.8mg * P<.5 - 4.03mg n.s.s. 3/77 1/45 3/38 3793 M f swa wat 92w92 1314 0 7.80mg Toth;myco,68,121-128;1979 lun mix es 2.16mg P<.0005 + 1.32mg 3.73mg 15/99 43/49 liv mix es 8.66mg P<.0005 + 4.95mg 17.1mg 0/68 18/47 blv mix es 12.2mg P<.0005 + 6.17mg 39.7mg 8/99 17/49 liv bhp es 17.5mg P<.0005 8.50mg 45.0mg 0/68 10/47 liv lcc es 22.4mg P<.0005 10.1mg 66.6mg 0/68 8/47 gal mix es 31.3mg P<.003 + 11.9mg 164.mg 0/63 5/40 gal ade es 39.7mg P<.006 13.7mg 449.mg 0/63 4/40 3794 M m swa wat 65w72 1110 0 13.0mg 26.0mg Toth;jnci,60,201-204;1978 liv mix aes 16.8mg \ P<.0005 + 8.19mg 48.2mg 1/81 11/47 (3/26) bil mix aes 36.2mg * P<.003 + 13.8mg 203.mg 0/75 5/29 0/8 gal ade aes 38.0mg \ P<.002 + 14.4mg 186.mg 0/81 5/47 (0/26) lun mix aes 14.2mg \ P<.02 + 6.00mg n.s.s. 22/98 20/47 (4/26) 3795 M m swa wat 22m23 1265 0 1.67mg 3.33mg Toth;nplm,27,25-31;1980 lun mix ae 1.72mg * P<.0005 + 1.12mg 3.09mg 22/98 36/49 31/46 blv mix ae 3.47mg \ P<.0005 + 1.64mg 14.5mg 5/78 13/42 (7/36) liv mix ae 5.47mg * P<.0005 + 3.10mg 12.2mg 2/78 6/42 14/36 gal mix ae 9.10mg * P<.0005 + 4.90mg 20.0mg 0/90 6/46 8/43 gal ade ae 9.88mg * P<.0005 5.21mg 22.8mg 0/90 6/46 7/43 3796 M m swa wat 23m24 1266 0 .417mg .833mg Toth;myco,78,11-16;1982a lun mix aes .865mg * P<.0005 + .488mg 2.69mg 19/83 27/45 24/47 lun ade aes 1.30mg * P<.002 .686mg 5.95mg 13/83 20/45 18/47 stg pla aes 3.43mg \ P<.01 - 1.04mg 215.mg 0/80 3/39 (0/43) lun adc aes 2.48mg * P<.03 1.08mg n.s.s. 9/83 14/45 11/47 sub fbs aes 2.60mg \ P<.02 - .916mg n.s.s. 1/83 5/45 (0/47) for sqp aes 11.2mg * P<.02 - 3.38mg n.s.s. 0/80 0/39 3/43 liv mix aes no dre P=1. 3.97mg n.s.s. 5/80 3/39 2/43 3797 M m swa wat 82w82 1314 0 6.50mg Toth;myco,68,121-128;1979 liv mix es 1.03mg P<.0005 + .527mg 1.99mg 1/69 28/30 lun mix es 1.87mg P<.0005 + 1.07mg 3.78mg 22/88 34/41 bil cho es 12.4mg P<.0005 + 5.05mg 44.5mg 0/69 6/30 gal ade es 15.2mg P<.0005 + 5.75mg 64.6mg 0/69 5/30 sev ade es 20.7mg P<.009 - 6.27mg 618.mg 0/51 3/24

SMILES Code for N-Methyl-N-formylhydrazine: CN(N)C=O
InChI Code for N-Methyl-N-formylhydrazine: InChI=1/C2H6N2O/c1-4(3)2-5/h2H,3H2,1H3
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for N-Methyl-N-formylhydrazine: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10